Bevacizumab is FDA-approved for @entity1 with recurrent GBM. However, the median duration of response is only 4  months. Potential mechanisms of resistance include upregulated FGF signaling and increased PDGF-mediated pericyte coverage. @entity9815 is an oral, small-molecule @entity669 kinase inhibitor of @entity675 /b, FGFR 1-3, and @entity6758 -3 that may overcome resistance to anti-VEGF therapy. This was a two-stage phase II trial in adults with first or second recurrence of GBM, stratified by prior bevacizumab therapy (ClinicalTrials.gov number NCT01380782; 1199.94). The primary endpoint was PFS6 in the bevacizumab-naive arm (Arm A) and PFS3 in the post-bevacizumab arm (Arm B). Up to 10 @entity11 ( @entity11 ) @entity1 were accrued to each arm in exploratory cohorts. Twenty-two @entity1 enrolled in Arm A and 14 in Arm B. Arm A included 12 GBMs (55  %), 13 @entity1 with one prior regimen (59  %), and median age 54  years (range 28-75). Arm B included 10 GBMs (71  %), one @entity1 with one prior regimen (7  %), and median age 52  years (range 32-70). Median KPS overall was 90 (range 60-100). There were no responses. In Arm A (GBM only), PFS6 was 0  %, median PFS 28  days (95  % CI 27-83), and median OS 6.9  months (3.7-8.1). In Arm B (GBM only), PFS3 was 0  %, median PFS 28  days (22-28), and median OS 2.6  months (1.0-6.9). Among @entity11 @entity1 in each arm, PFS6 was 0  %. Treatment was well tolerated. In conclusion, @entity9815 is not active against recurrent high-grade @entity11 , regardless of prior bevacizumab therapy.

Phase II trial of triple XXXX kinase receptor inhibitor @entity9815 in recurrent high-grade @entity11 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity675 :: ('5156', 'Gene') :: ['PDGFR a'] @entity9815 :: ('MESH:C530716', 'Chemical') :: ['nintedanib', 'Nintedanib'] @entity11 :: ('MESH:D005910', 'Disease') :: ['AG', 'anaplastic glioma', 'glioma'] @entity6758 :: ('2321', 'Gene') :: ['VEGFR 1'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']
@entity669 :: (CHEBI:18186,Chemical) :: ['tyrosine']
